Chagas disease is a potentially life-threatening parasitic disease that affects up to 300,000 people in the United States and millions in South America.
The current treatment regimen is–oral benznidazole in smaller twice-daily doses over 2 months
My guest today and his colleagues say high weekly doses of oral benznidazole over 30 weeks resulted in better clearance of the parasite.
This research is outlined in a recent study published in the journal Science Translational Medicine.
Joining me today is Regents’ Professor in the University of Georgia’s department of cellular biology, Rick Tarleton, PhD
Show notes: A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease
Podcast: Play in new window | Download
Subscribe: Apple Podcasts | RSS
Related:
Chagas disease: 1st local transmission in Missouri
Chagas disease, kissing bugs and the OSU survey
Neglected Tropical Diseases: Chagas disease and schistosomiasis
Chagas disease treatment, Lampit, receives FDA approval for use in children
Texas reports increase in kissing bugs, Could increase Chagas risk
World Chagas Disease Day: Raising awareness about the ‘silent and silenced disease’
3 thoughts on “Chagas disease treatment research with Rick Tarleton, PhD”